Navigation Links
Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
Date:11/12/2009

PLEASANTON, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it will webcast its investor event to discuss data from the HeartMate II Destination Therapy clinical trial that will be presented during the late-breaking clinical trial session at the American Heart Association(AHA) Scientific Sessions 2009.

The event will begin at 1:30 p.m., Eastern Standard Time (10:30 a.m., Pacific Standard Time), on Tuesday, November 17. The event will be available through the company's website at www.thoratec.com. It will also be archived on the company's website.

The event will include a review of the trial data by Dr. Joseph Rogers of Duke University, who is presenting the data at AHA as a late-breaking clinical trial, and comments from Gary F. Burbach, president and chief executive officer of Thoratec.

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec® VAD (Ventricular Assist Device) and HeartMate® LVAS (Left Ventricular Assist System), with more than 14,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) Division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's websites at http://www.thoratec.com or http://www.itcmed.com.

SOURCE Thoratec Corporation


'/>"/>
SOURCE Thoratec Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Presentation at Canaccord Adams Conference to be Webcast
5. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
6. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
7. Oculus Innovative Sciences to Present at 4th Annual BIO InvestorForum Conference
8. BD to Present at Investor Healthcare Conferences
9. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
10. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
11. CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... , June 14, 2017 The Bio ... City of Fremont and the ... the bio-pharma industry in California ... enabling executive networking, and fostering workforce development. The primary ... and growth of start-ups, as well as small and ...
(Date:6/13/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global ... and Drug Administration (FDA) has notified the Company that the ... Zhejiang, China manufacturing facility has been closed ... of the Warning Letter related to our ... the progress we have made in our ongoing quality and ...
(Date:6/11/2017)... INDIANAPOLIS , June 10, 2017  Eli Lilly and ... results from three Phase 3 studies of galcanezumab, an ... migraine, including late-breaking data on several key secondary endpoints ... Detailed results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) ... (AHS) annual scientific meeting in Boston ...
Breaking Medicine Technology:
(Date:6/22/2017)... (PRWEB) , ... June 23, 2017 , ... ... in the fight against hunger on June 21, 2017, at the Emeryville Center ... food insecurity and malnutrition around the world. , Rise Against Hunger (formerly Stop ...
(Date:6/20/2017)... ... June 20, 2017 , ... Connance, a leading provider of ... how predictive analytics drive reimbursement optimization, with a focus on denial management and ... , “The traditional approach to denied and underpaid claims leaves money on the ...
(Date:6/20/2017)... ... ... months of negotiations, FaceCradle USA is proud to announce the debut of FaceCradle travel ... product on QVC is something we all worked hard to achieve for many months, and ... million homes in the United States,” said FaceCradle USA President Dylan Doherty. “We can’t wait ...
(Date:6/20/2017)... PA (PRWEB) , ... June 20, 2017 , ... ... assessments and consulting services, has published a new eBook titled “ 5 Questions ... Bridge, MSc, Associate Research Analyst on the Genetic Test Evaluation (GTE) team, the ...
(Date:6/20/2017)... ... June 20, 2017 , ... Kenneth Mayer, MD, has been ... (JIAS). , Dr. Mayer, who joined the JIAS Editorial Board in 2016, has co-authored ... Research Director of Fenway Health and Co-Chair of The Fenway Institute, a ...
Breaking Medicine News(10 mins):